Badrinath Konety and Alicia Morgans discuss biomarkers in bladder cancer. Concepts highlighted include incorporating clinical and other disease characteristics into biomarkers, so outcomes can be more accurately predicted. 

Biographies:
Badrinath Konety, MD, MBA, is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-Oncology and is Director of the Institute for Prostate and Urologic Cancers. He is also Associate Director, Clinical Affairs & Clinical Research, Masonic Cancer Center (MCC)

Alicia Morgans, MD, MPH

Read More:

Bladder Cancer BioMarkers: Optimal Utilization for Diagnosis and Recurrence

Watch: Bladder Cancer Biomarkers: Optimal utilization for diagnosis and recurrence pipeline- Badrinath Konety